Highest-materiality recent filing
IGC Pharma raises $514K via two convertible promissory notes with OID
FirstFire note: $346,910 principal at $307K purchase price, OID $39,910, 12% interest, matures April 10, 2027.
IGC Pharma increases authorized common stock from 150M to 600M shares
Amendment effective Dec 12, 2025, after stockholder approval on Oct 10, 2025.
IGC Pharma shareholders approve 4x increase in authorized shares to 600M and 5M share grant
Shareholders approved amendment to increase authorized common stock from 150M to 600M shares.
IGC Pharma subsidiary sells assets and facility to Wellness Essentials for ~$2.7M
Holi Hemp sold equipment, inventory, and Vancouver ready-to-move facility to Wellness Essentials Northwest.
IGC Pharma Phase 2 CALMA trial shows significant agitation reduction in Alzheimer's patients
Phase 2 interim: CMAI total score improvement -10.46 at week 6 (p=0.042, Cohen d=0.79) vs placebo.
IGC Pharma reports positive interim Phase 2 results for IGC-AD1 in Alzheimer's agitation
Cohen's d effect size at week 6=0.66, CMAI LS mean difference vs placebo=-10.45, p=0.037.
IGC Pharma appoints Terry Lierman as independent director to advance Alzheimer's pipeline
Terry Lierman appointed as independent Class B director, effective March 12, 2024.
On March 12, 2024, the Board of Directors (the “Board”) of IGC Pharma, Inc. (the “Company” or “IGC”) appointed Mr. Terry Lierman (“Mr. Lierman”) to serve on the Board as a Class B director.
Max materiality 0.85 · Median 0.55 · Most common event other_material